Evidence map›Paper›PMID 31173184›Full record

ArticleInternational journal of oncology2019

Adenylyl cyclase‑associated protein 1‑targeted nanoparticles as a novel strategy for the treatment of metastatic non‑small cell lung cancer.

Yang Liu, Shuanshuan Xie, Jie Zeng, Xiaolian Song, Min Tan, Dannong He, Jie Wang, Ping Wang, Jun Zhu, Changhui Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yang LiuDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
Shuanshuan XieDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
Jie ZengDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
Xiaolian SongDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
Min TanDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
Dannong HeNational Engineering Research Center for Nanotechnology, Shanghai 200241, P.R. China.
Jie WangNational Engineering Research Center for Nanotechnology, Shanghai 200241, P.R. China.
Ping WangNational Engineering Research Center for Nanotechnology, Shanghai 200241, P.R. China.
Jun ZhuNational Engineering Research Center for Nanotechnology, Shanghai 200241, P.R. China.
Changhui WangDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China.
National Engineering Research Center for Nanotechnology · CNShanghai Tenth People's Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑small cell lung cancer (NSCLC) is one of the most fatal cancers worldwide. Adenylyl cyclase‑associated protein 1 (CAP1) belongs to a family of cyclase‑associated proteins that are involved in the development of cancerous tumors. A previous study by our group confirmed the association between CAP1, lung cancer and the metastasis of cancer cells. In the present study, poly(lactic‑polyglycolic acid; PLGA)/CAP1‑small interfering (si)RNA nanoparticles were prepared and delivered into A549 cells. The performance of PLGA/siCAP1‑siRNA nanoparticles for siRNA delivery was measured based on the results of migration assay and animal experiments. The multifunctional nanoparticles were determined to be capable of inhibiting CAP1 expression, which reduced NSCLC metastasis in vitro and in vivo. Therefore, the findings of the current study highlighted the potential use of PLGA/siCAP1‑siRNA nanoparticles for the treatment of NSCLC metastasis.

Indexed as

AnimalsApoptosisCarcinoma, Non-Small-Cell LungCell Cycle ProteinsCell MovementCell ProliferationCytoskeletal ProteinsHumansLung NeoplasmsMaleMiceMice, NudeNanoparticlesRNA, Small InterferingTumor Cells, CulturedXenograft Model Antitumor AssaysCAP1 protein, humanCell Cycle ProteinsCytoskeletal ProteinsRNA, Small Interfering

Identifiers

PMID31173184
PMCPMC6615927
OpenAlexW2948744146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.